CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly EBT Margin came in at 4267.12% in Q1 2026, down 418693.0% YoY from N/an in Q1 2025, and up 91.99% on a QoQ basis from 53305.0% in Q4 2025.
CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of EBT Margin data on file, last reported at 4267.12% in Q1 2026.
- Quarterly EBT Margin fell 418693.0% year-over-year to 4267.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9107.2% (down 883264.0% YoY) and the FY2025 annual result came in at 1684.35%, up 594283.0% from the prior year.
- EBT Margin grew to 4267.12% in Q1 2026, from 53305.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 4289.8% in Q1 2024 to a low of 112400.0% in Q3 2024.
- A 5-year average of 14243.5% and a median of 2277.16% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin sank 11239999 bps — and 2025, when it soared 10784545 bps.
- Tracing CLGN's EBT Margin over 5 years: stood at 46796.55% in 2022, then surged by 96 bps to 1679.93% in 2023, then tumbled by 71 bps to 2874.39% in 2024, then sank by 1754 bps to 53305.0% in 2025, then jumped by 92 bps to 4267.12% in 2026.
- The last three EBT Margin figures came in at 4267.12% (Q1 2026), 53305.0% (Q4 2025), and 4554.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | CollPlant Biotechnologies | 4.40 Mn | 4.40 Mn | -243,000.00 | -4,267.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -53,305.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -2,874.39% |
| Sep 30, 2024 | -112,400.00% |
| Jun 30, 2024 | 1,634.94% |
| Mar 31, 2024 | 4,289.80% |
| Dec 31, 2023 | -1,679.93% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 54.05% |
| Mar 31, 2023 | 747.58% |
| Dec 31, 2022 | -46,796.55% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -73,640.97% |
| Sep 30, 2021 | 51,361.43% |
| Jun 30, 2021 | -431.69% |
| Mar 31, 2021 | 69.62% |